Wijsenbeek, M;
Kreuter, M;
Olson, A;
Fischer, A;
Bendstrup, E;
Wells, CD;
Denton, CP;
... Cottin, V; + view all
(2019)
Progressive Fibrosing Interstitial Lung Diseases: Current Practice in Diagnosis and Management.
Current Medical Research and Opinion
, 35
(11)
pp. 2015-2024.
10.1080/03007995.2019.1647040.
Preview |
Text
Denton_Progressive fibrosing interstitial lung diseases current practice in diagnosis and management.pdf - Published Version Download (3MB) | Preview |
Abstract
Objective: Some patients with interstitial lung diseases (ILDs) other than idiopathic pulmonary fibrosis (IPF) develop a progressive fibrosing phenotype. We investigated the diagnosis and management of non-IPF ILDs using data from a survey of physicians and from US insurance claims. // Methods: Pulmonologists, rheumatologists and internists in France, Germany, Italy, Japan, Spain, UK and US who had managed ≥10 patients with non-IPF ILDs in the past year, including those with progressive fibrosing ILDs, completed an online survey. Data on US insurance and prescription claims were obtained from a repository that aggregates data on claims routed from providers or pharmacies to payers. // Results: In May-June 2017, 243 pulmonologists, 203 rheumatologists, and 40 internists completed an on-line survey. Respondents estimated that 18-32% of patients diagnosed with non-IPF ILDs develop progressive fibrosis and that time from symptom onset to death in these patients was 61-80 months. Drug treatment was given to 50-75% of patients with non-IPF progressive fibrosing ILDs Reasons for patients not being treated included that physicians considered patients to have mild or slowly progressing disease, or did not believe that available treatments are effective or well tolerated. Corticosteroids were the preferred first-line treatment for all types of non-IPF ILD. There was considerable heterogeneity in preferences for second- and third-line treatments. US insurance claims data from 3823 patients indicated that in 2016, 50-75% of patients with ILDs received drug treatment (mostly corticosteroids) for their ILD. // Conclusions: Physicians estimate that 18-32% of patients diagnosed with non-IPF ILDs develop a progressive fibrosing phenotype and that these patients experience significant delays in the diagnosis of ILD and the detection of progressive fibrosis. Between 25 and 50% of patients with progressive fibrosing ILDs do not receive drug therapy. There is an unmet need for effective and well-tolerated treatments for progressive fibrosing ILDs.
| Type: | Article |
|---|---|
| Title: | Progressive Fibrosing Interstitial Lung Diseases: Current Practice in Diagnosis and Management |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1080/03007995.2019.1647040 |
| Publisher version: | https://doi.org/10.1080/03007995.2019.1647040 |
| Language: | English |
| Additional information: | � 2019 Boehringer Ingelheim. Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4. 0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, |
| Keywords: | disease management, drug therapy, immunosuppression, pulmonologist, rheumatologist, survey |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Medicine > Inflammation |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10078922 |
Archive Staff Only
 |
View Item |
